15
Biodrugs 2008; 22 (5) 315-329DRUG DEVELOPMENT 1173-8804080005-0315$48.pdf
Biodrugs 2008; 22 (5) 315-329DRUG DEVELOPMENT 1173-8804080005-0315$48
18
adeno-associated virus (aav) as a vector for gene therapy.[2017][biodrugs][10.1007s40259-017-0234-5].pdf
adeno-associated virus (aav) as a vector for gene therapy.[2017][biodrugs][10.1007s40259-017-0234-5]
22
cell-free protein synthesis_ a promising option for future drug development.[2020][biodrugs].pdf
cell-free protein synthesis_ a promising option for future drug development.[2020][biodrugs]
28
applying antibodies inside cells_ principles and recent advances in neurobiology, virology and oncology.[2020][biodrugs].pdf
applying antibodies inside cells_ principles and recent advances in neurobiology, virology and oncology.[2020][biodrugs]
36
biosimilars for the treatment of cancer a systematic review of published evidence.[2017][biodrugs clinical immunotherape.生物仿制药治疗癌症的系统回顾发表的证据。[2017][bio.pdf
biosimilars for the treatment of cancer a systematic review of published evidence.[2017][biodrugs clinical immunotherape.生物仿制药治疗癌症的系统回顾发表的证据。[2017][bio
10
the path towards a tailored clinical biosimilar development.[2020][biodrugs].pdf
the path towards a tailored clinical biosimilar development.[2020][biodrugs]
26
biosimilarity and interchangeability principles and evidence a systematic review.[2018][biodrugs][10.1007s40259-017-0256-z].pdf
biosimilarity and interchangeability principles and evidence a systematic review.[2018][biodrugs][10.1007s40259-017-0256-z]
9
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.[2020][BioDrugs].pdf
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.[2020][BioDrugs]
12
identifying key benefits in european off-patent biologics and biosimilar markets_ it is not only about price![2019][biodrugs].pdf
identifying key benefits in european off-patent biologics and biosimilar markets_ it is not only about price![2019][biodrugs]

向豆丁求助:有没有biodrugs?

如要投诉违规内容,请联系我们按需举报;如要提出意见建议,请到社区论坛发帖反馈。